Target (NYSE:TGT) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, March 2nd. Analysts expect Target to post earnings of $2.47 per share for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.
Shares of TGT opened at $188.99 on Tuesday. The stock has a market capitalization of $94.64 billion, a P/E ratio of 25.03, a P/E/G ratio of 2.64 and a beta of 0.97. Target has a twelve month low of $90.17 and a twelve month high of $199.96. The company has a 50 day moving average of $189.95 and a 200-day moving average of $167.31. The company has a quick ratio of 0.39, a current ratio of 1.05 and a debt-to-equity ratio of 0.94.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 10th. Stockholders of record on Wednesday, February 17th will be paid a dividend of $0.68 per share. The ex-dividend date of this dividend is Tuesday, February 16th. This represents a $2.72 annualized dividend and a dividend yield of 1.44%. Target's dividend payout ratio is currently 42.57%.
In other news, insider Stephanie A. Lundquist sold 16,894 shares of Target stock in a transaction on Thursday, January 14th. The stock was sold at an average price of $198.34, for a total transaction of $3,350,755.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.52% of the company's stock.
A hedge fund recently bought a new stake in Target stock. OLD Mission Capital LLC bought a new position in shares of Target Co. (NYSE:TGT) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,268 shares of the retailer's stock, valued at approximately $200,000. Institutional investors own 79.17% of the company's stock.
Several equities analysts have recently weighed in on the stock. MKM Partners raised shares of Target from a "sell" rating to a "neutral" rating and raised their price target for the stock from $127.00 to $156.00 in a research note on Thursday, November 19th. Stifel Nicolaus reaffirmed a "hold" rating and set a $200.00 price target on shares of Target in a research note on Tuesday, February 16th. Morgan Stanley raised their target price on shares of Target from $180.00 to $195.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 20th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Target from $194.00 to $211.00 and gave the company a "buy" rating in a research note on Thursday, January 14th. Finally, Raymond James raised their target price on shares of Target from $180.00 to $200.00 and gave the company a "strong-buy" rating in a research note on Thursday, November 19th. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. The company currently has an average rating of "Buy" and a consensus target price of $165.29.
Target Corporation operates as a general merchandise retailer in the United States. The company offers food assortments, including perishables, dry grocery, dairy, and frozen items; apparel, accessories, home dÃ©cor products, electronics, toys, seasonal offerings, and other merchandise; beauty and household essentials; The company also provides in-store amenities, such as Target CafÃ©, Target Optical, Starbucks, and other food service offerings.
Featured Story: Understanding Analyst Ratings
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Healthcare Stocks Delivering Innovation in 2021
We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.
Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.
However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.
That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.
View the "7 Healthcare Stocks Delivering Innovation in 2021".